Drugs / Imatinib
Imatinib
also known as
Imatinib Mesylate · Gleevec · STI 571 · Glivec · QTI571 · Gleevec (imatinib mesylate) · Imatinib Mesilate · NSC #716051 · +12 more
Small molecule targets ABL1, ABL2, BCR, CYP2D6, CYP3A4, KIT, PDGFRA, PDGFRB, SYK via inhibition
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (16) | US (FDA) | GLEEVEC | — | 2002-02-01 – 2016-08-25 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Ruvise | — | 2013-02-22 | europa.eu ↗ |
| Approved | EU (EMA) | Glivec | — | 2001-11-07 | europa.eu ↗ |
| Approved | US (FDA) | GLEEVEC | — | 2001-05-10 | fda.gov ↗ |
Trials 427 · started per year
today
US approved 2001
EU approved 2001
1
3
11
21
46
33
42
29
29
25
19
14
10
10
14
9
11
11
8
8
9
8
17
11
5
6
2
5
7
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05816785 | Apr 2023 → Aug 2026 | head and neck squamous cell carcinoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT04006769 | Oct 2020 → Aug 2022 | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 164 trials · 2 met primary | ||||||
| Phase 1 | NCT07171203 | May 2026 → Jul 2030 expected | gastrointestinal stromal tumor | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1 | NCT06962254 | May 2025 → Mar 2028 expected | — | China Medical University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06090669 | Dec 2023 → Oct 2026 expected | bone marrow failure syndrome, hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT05245968 | Dec 2021 → Dec 2026 expected | gastrointestinal stromal tumor | Taiho Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04903730 | May 2021 → Dec 2022 | pulmonary arterial hypertension | Aerami Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03469011 | Sep 2018 → Jul 2024 | thyroid gland papillary carcinoma | AHS Cancer Control Alberta | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02614404 | Nov 2015 → Dec 2016 | Plasmodium falciparum malaria | HuLow | Completed | No outcome recorded |
| Phase 1 | NCT02352558 | May 2015 → Dec 2018 | hematopoietic and lymphoid system neoplasm | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02268435 | Mar 2015 → Aug 2016 | gastrointestinal stromal tumor | Asan Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01735968 | Feb 2013 → Oct 2018 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01738139 | Feb 2013 → Dec 2022 | cutaneous melanoma, gastrointestinal stromal tumor, metastatic malignant neoplasm, metastatic melanoma | M.D. Anderson Cancer Center | Completed | Met primary |
| Phase 1 | NCT01751919 | May → Aug 2012 | chronic myeloid leukemia, gastrointestinal stromal tumor | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01468688 | Apr 2012 → Jul 2016 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01568645 | Mar → Dec 2012 | pulmonary hypertension | National Heart, Lung, and Blood Institute (NHLBI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT01504984 | Mar → Apr 2012 | — | Samyang Biopharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01926548 | Feb → Mar 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01653314 | Jan → Mar 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT01175109 | Oct 2011 → Dec 2013 | chordoma | Deric M Park MD | Unknown | No outcome recorded |
| Phase 1 | NCT01404715 | Oct 2011 → Mar 2013 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01270984 | Nov → Dec 2010 | chronic myeloid leukemia, gastrointestinal stromal tumor | Chong Kun Dang Pharmaceutical | Completed | Met primary |
| Phase 1 | NCT01066468 | Oct 2010 → May 2011 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), chronic myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01046487 | Feb 2009 → Apr 2011 | cancer | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 1 | NCT00732784 | Nov 2008 → Nov 2012 | — | Jan Beumer | Completed | No outcome recorded |
| Phase 1 | NCT00760981 | Sep 2008 → Apr 2012 | chronic graft versus host disease | David Miklos | Completed | No outcome recorded |
| Phase 1 | NCT00613054 | Nov 2007 → Mar 2009 | gliosarcoma | Annick Desjardins | Completed | No outcome recorded |
| Phase 1 | NCT00601510 | Nov 2007 → Jan 2011 | gastric cancer | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT01271166 | Oct 2007 → Aug 2009 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00573404 | Jul 2007 → Sep 2009 | gastrointestinal stromal tumor | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00446004 | Apr 2007 → Aug 2009 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT00446316 | Apr 2007 → Oct 2008 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT00424385 | Jan 2007 → Feb 2012 | prostate cancer | Oncology Specialists, S.C. | Completed | No outcome recorded |
| Phase 1 | NCT00441155 | Nov 2006 → Jan 2011 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00403156 | Nov 2006 → ? | choroidal neovascularization | Vitreous -Retina- Macula Consultants of New York | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00428909 | Nov 2006 → Aug 2008 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00401024 | Oct 2006 → Feb 2008 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00420043 | Sep → Nov 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00390156 | Aug 2006 → Jan 2011 | cancer of unknown primary site | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00402766 | Aug 2006 → Feb 2014 | mesothelioma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01048320 | Jul 2006 → Dec 2010 | malignant exocrine pancreas neoplasm | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT00422825 | Jun → Sep 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00314873 | Apr 2006 → Mar 2011 | thymic carcinoma | Indiana University | Completed | No outcome recorded |
| Phase 1 | NCT00135005 | Aug 2005 → Nov 2006 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00387933 | Jul 2005 → Jan 2009 | central nervous system neoplasm | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT00613132 | May 2005 → Aug 2008 | gliosarcoma | Annick Desjardins | Completed | No outcome recorded |
| Phase 1 | NCT00101088 | Apr 2005 → Jun 2010 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive, leukemia, myeloid, accelerated-phase | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00281996 | Mar 2005 → Oct 2008 | malignant pancreatic neoplasm | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00258271 | Mar 2005 → Oct 2006 | leukemia | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT00084513 | Aug 2004 → Mar 2007 | — | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00611689 | Jul 2004 → Jan 2008 | refractory malignant neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00354068 | Jul 2004 → Nov 2008 | central nervous system neoplasm | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT00080665 | Dec 2003 → Jan 2007 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00253565 | Aug 2003 → Jul 2006 | cancer of unknown primary site | Herbert Hurwitz | Completed | No outcome recorded |
| Phase 1 | NCT00268229 | Jul 2003 → Aug 2011 | leukemia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00064285 | Jun 2003 → ? | leukemia | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT00052494 | Apr 2003 → Feb 2009 | lung cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT00183833 | Dec 2002 → Jul 2009 | colon carcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00047502 | Nov 2002 → Apr 2006 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00040105 | Oct 2002 → Mar 2009 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00045604 | Jul 2002 → ? | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00004932 | Jan 2002 → Sep 2005 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00038194 | Oct 2001 → Sep 2005 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00026169 | Sep 2001 → Apr 2005 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00025415 | Aug 2001 → Jan 2005 | AIDS-related primary central nervous system lymphoma, Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma +37 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/248 trials · 1 met primary · 1 missed | ||||||
| Phase 1/2 | NCT06626984 | Dec 2024 → Feb 2026 overdue | infectious disease with sepsis | Belfast Health and Social Care Trust | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05224128 | Feb 2021 → Feb 2022 | fibrotic liver disease | Research Institute for Gastroenterology and Liver Diseases (RIGLD) | Unknown | No outcome recorded |
| Phase 1/2 | NCT04546074 | Sep 2020 → Oct 2024 | melanoma | Keio University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03997903 | Feb 2020 → Aug 2024 | sickle cell disease | Indiana University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04138381 | Aug 2019 → Apr 2023 | gastrointestinal stromal tumor, poisoning, soft tissue sarcoma, substance abuse | Spanish Group for Research in Sarcomas | Unknown | No outcome recorded |
| Phase 1/2 | NCT03802084 | Apr 2019 → Mar 2024 | desmoid tumor | Hyo Song Kim | Completed | No outcome recorded |
| Phase 1/2 | NCT03609424 | Feb 2019 → Nov 2021 | gastrointestinal stromal tumor | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03131999 | Jan 2018 → Mar 2019 | lymphangioleiomyomatosis | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT02812693 | Nov 2016 → Nov 2017 | cutaneous melanoma | Joanne Jeter | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02462538 | Nov 2015 → Nov 2021 | ALK-positive anaplastic large cell lymphoma | Study Group of Medical Tumour Therapy (AGMT) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02431403 | Feb 2015 → Feb 2020 | non-Hodgkin lymphoma | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01991379 | Nov 2013 → Nov 2026 expected | gastrointestinal stromal tumor | Memorial Sloan Kettering Cancer Center | Active not recruiting | Met primary |
| Phase 1/2 | NCT01140360 | Feb 2012 → Aug 2016 | neurofibroma, neurofibromatosis type 1 | Kent Robertson | Completed | No outcome recorded |
| Phase 1/2 | NCT01281865 | Jan 2011 → Oct 2013 | synovial sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01383447 | Oct 2010 → Apr 2012 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00867334 | Jun 2009 → Aug 2011 | colorectal cancer | Inova Health Care Services | Completed | No outcome recorded |
| Phase 1/2 | NCT00891527 | Oct 2008 → Dec 2015 | pulmonary venoocclusive disease | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00702403 | Aug 2008 → Dec 2013 | adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia, leukemia, myeloid, accelerated-phase | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00512902 | Aug 2007 → Nov 2008 | pneumonitis, systemic sclerosis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT00506831 | Jul 2007 → Sep 2010 | systemic sclerosis | Stanford University | Completed | No outcome recorded |
| Phase 1/2 | NCT00426179 | Dec 2006 → Aug 2007 | seasonal allergic rhinitis | Novartis | Completed | No outcome recorded |
| Phase 1/2 | NCT00558961 | Oct 2005 → Apr 2009 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Jewish General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00417807 | Aug 2005 → Jun 2009 | desmoplastic small round cell tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00861471 | May 2005 → May 2010 | prostate cancer | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00354523 | Dec 2004 → Nov 2006 | thyroid cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02127372 | Nov 2004 → Jun 2010 | non-small cell lung carcinoma | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00287846 | Sep 2004 → Feb 2006 | desmoid tumor | UNICANCER | Completed | No outcome recorded |
| Phase 1/2 | NCT00093639 | Aug 2004 → Aug 2006 | myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01126814 | Jul 2004 → Sep 2009 | leukemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00088231 | Jul 2004 → Oct 2006 | acute myeloid leukemia, chronic myeloid leukemia, myelofibrosis with myeloid metaplasia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00193258 | Jun 2004 → Jan 2011 | clear cell renal carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02480608 | Apr 2004 → Aug 2011 | chronic myeloid leukemia | University of Leipzig | Completed | Missed primary |
| Phase 1/2 | NCT00244829 | Jan 2004 → Aug 2007 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00122473 | Jan 2004 → Jan 2007 | connective and soft tissue neoplasm | Dermatologic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00506779 | Dec 2003 → Apr 2015 | uterine carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00081133 | Dec 2003 → Feb 2005 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00074308 | Oct 2003 → Jul 2009 | metastatic melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00061945 | Jun 2003 → Dec 2007 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00049127 | Jun 2003 → Aug 2011 | adult oligodendroglioma, anaplastic oligodendroglioma, brain neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00667953 | Jan 2003 → Mar 2011 | melanoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01275222 | Nov 2002 → Sep 2008 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00053248 | Oct 2002 → Jun 2005 | leukemia | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00021229 | May 2001 → Aug 2008 | central nervous system neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00015860 | May 2001 → Oct 2003 | leukemia | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00015834 | May 2001 → Apr 2003 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00028847 | Apr 2001 → ? | leukemia | Commissie Voor Klinisch Toegepast Onderzoek | Unknown | No outcome recorded |
| Phase 1/2 | NCT00010049 | Feb 2001 → Mar 2005 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/2 | NCT00006357 | Aug 2000 → Apr 2001 | endometrial cancer, gastrointestinal stromal tumor, ovarian cancer, sarcoma +1 | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2230 trials · 8 met primary · 11 missed | ||||||
| Phase 2 | NCT07406633 | Jun 2026 → Oct 2027 expected | gastrointestinal stromal tumor | Kumquat Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07124078 | May 2026 → Jan 2029 expected | chronic graft versus host disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT07559370 | Jan 2026 → Jun 2027 expected | Plasmodium falciparum malaria | Victoria Biomedical Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07022743 | Jul 2025 → Jul 2026 overdue | chronic myeloid leukemia | Obafemi Awolowo University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06124157 | May 2025 → Dec 2030 expected | B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06119789 | Mar 2025 → Nov 2033 expected | high grade malignant neoplasm | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05493215 | Mar 2024 → Dec 2027 expected | gastrointestinal stromal tumor | Reema A. Patel | Recruiting | No outcome recorded |
| Phase 2 | NCT06061094 | Jul 2023 → Jul 2029 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Goethe University | Recruiting | No outcome recorded |
| Phase 2 | NCT05385549 | Sep 2022 → Apr 2030 expected | gastrointestinal stromal tumor | Asan Medical Center | Recruiting | No outcome recorded |
| Show all 230 trials opens the full record — a long page | ||||||
| Phase 2/35 trials · 3 missed | ||||||
| Phase 2/3 | NCT05036135 | Dec 2021 → Aug 2024 | pulmonary arterial hypertension | Aerovate Therapeutics | Terminated | Missed primary |
| Phase 2/3 | NCT03624530 | Aug 2018 → Jul 2021 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00427583 | May 2006 → Apr 2009 | malignant peripheral nerve sheath tumor | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00477269 | Apr 2006 → Jan 2014 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2/3 | NCT00131274 | Apr 2003 → Aug 2007 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Daniels, Craig E., M.D. | Completed | Missed primary |
| Phase 347 trials · 9 met primary · 3 missed | ||||||
| Phase 3 | NCT07585266 | Jul 2026 → Aug 2032 expected | gastrointestinal stromal tumor | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07530367 | Apr 2026 → Apr 2028 expected | palmoplantar pustulosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05413915 | Nov 2023 → Jul 2025 | chronic myeloid leukemia | Sarit Assouline | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05970900 | Oct 2023 → Oct 2026 expected | colorectal gastrointestinal stromal tumor | Fujian Medical University Union Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04307576 | Jul 2020 → Jun 2033 expected | acute lymphoblastic leukemia | Mats Heyman | Recruiting | No outcome recorded |
| Phase 3 | NCT04394416 | Jun 2020 → Jun 2024 | COVID-19 | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 3 | NCT04422678 | Jun → Sep 2020 | COVID-19 | Alexandria University | Unknown | No outcome recorded |
| Phase 3 | NCT04330690 | Mar 2020 → Mar 2024 | COVID-19 | Sunnybrook Health Sciences Centre | Unknown | Missed primary |
| Phase 3 | NCT03632135 | May 2018 → Jun 2022 | glioblastoma | Cordgenics, LLC | Completed | Met primary |
| Phase 3 | NCT03007147 | Aug 2017 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02881086 | Aug 2016 → Dec 2024 | acute lymphoblastic leukemia, lymphoblastic lymphoma | Goethe University | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02326311 | Jun 2015 → Dec 2023 | chronic myeloid leukemia | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Completed | No outcome recorded |
| Phase 3 | NCT02413736 | May 2015 → Jun 2026 overdue | sarcoma | Heikki Joensuu | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02260505 | Dec 2014 → Dec 2023 | gastrointestinal stromal tumor | Centre Leon Berard | Completed | Met primary |
| Phase 3 | NCT02174445 | Mar 2014 → Dec 2018 | chronic myeloid leukemia | Prof. Dr. Nikolas von Bubnoff | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02042014 | Jan 2014 → Oct 2016 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01819389 | Oct 2012 → Jul 2013 | chronic myeloid leukemia | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 3 | NCT01392495 | Jun 2011 → Mar 2014 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01392469 | Apr 2011 → Oct 2012 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01151852 | Jun 2010 → Mar 2013 | gastrointestinal stromal tumor | Asan Medical Center | Completed | Met primary |
| Phase 3 | NCT01117987 | Apr 2010 → Apr 2014 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00981942 | Sep 2009 → Dec 2010 | nephrogenic systemic fibrosis | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00902174 | Sep 2009 → May 2011 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01827930 | Jul 2009 → Jan 2017 | chronic myeloid leukemia | Institut Bergonié | Terminated | No outcome recorded |
| Phase 3 | NCT00324987 | Apr 2008 → Jul 2015 | gastrointestinal stromal tumor | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00471497 | Jul 2007 → Sep 2009 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00327678 | May 2006 → Apr 2014 | lymphoid leukemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00297570 | Feb 2006 → ? | Philadelphia-positive myelogenous leukemia | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00124748 | Jun 2005 → Nov 2010 | chronic myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00103168 | Dec 2004 → Oct 2008 | gastrointestinal stromal tumor | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 3 | NCT00154375 | Oct 2004 → Aug 2008 | astrocytoma (excluding glioblastoma), glioblastoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00514488 | Jun 2004 → ? | chronic myeloid leukemia | University of Bologna | Completed | Missed primary |
| Phase 3 | NCT00293124 | Mar 2004 → Jul 2006 | gastrointestinal stromal tumor | Central European Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00327262 | Jan 2004 → Dec 2008 | chronic myeloid leukemia | Central European Leukemia Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT00219739 | Sep 2003 → Dec 2014 | chronic myeloid leukemia | Poitiers University Hospital | Completed | Met primary |
| Phase 3 | NCT00237120 | Nov 2002 → Jun 2007 | chronic myeloid leukemia | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00022737 | Oct 2002 → Oct 2006 | childhood acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00041197 | Jun 2002 → Apr 2007 | gastrointestinal stromal tumor | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 3 | NCT00055874 | Jun 2002 → Mar 2012 | leukemia | Heidelberg University | Completed | Met primary |
| Phase 3 | NCT00367861 | May 2002 → Apr 2012 | gastrointestinal stromal tumor, sarcoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 3 | NCT00685828 | Jan 2001 → Feb 2002 | gastrointestinal stromal tumor | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3 | NCT00009906 | Dec 2000 → May 2007 | gastrointestinal stromal tumor | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00137111 | Jul 2000 → Nov 2010 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00333840 | Jun 2000 → Mar 2012 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00006343 | Jun 2000 → Mar 2007 | leukemia | Novartis | Completed | Met primary |
| Phase 3 | NCT00002514 | May 1993 → Dec 2006 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 418 trials · 1 met primary | ||||||
| Phase 4 | NCT07839988 | Sep 2026 → Jul 2030 expected | chronic myeloid leukemia | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04877522 | Aug 2022 → Aug 2030 expected | chronic myeloid leukemia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT05220280 | Feb 2022 → Dec 2024 | COVID-19 | Clinical Urology and Epidemiology Working Group | Unknown | No outcome recorded |
| Phase 4 | NCT05273242 | Dec 2021 → Dec 2022 | COVID-19 | Nepal Health Research Council | Unknown | No outcome recorded |
| Phase 4 | NCT02602314 | Nov 2016 → Feb 2023 | chronic myeloid leukemia | GIMEMA Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT03844360 | Jan 2016 → Dec 2025 overdue | hematopoietic and lymphoid cell neoplasm | Wei Zhao | Recruiting | No outcome recorded |
| Phase 4 | NCT02317159 | Feb 2015 → Jun 2017 | chronic myeloid leukemia | Cttq | Unknown | No outcome recorded |
| Phase 4 | NCT02204722 | Oct 2014 → May 2017 | chronic myeloid leukemia | Dong-A ST Co., Ltd. | Terminated | No outcome recorded |
| Phase 4 | NCT01742299 | Mar 2013 → Apr 2026 | chronic myeloid leukemia, gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01297777 | Jan 2011 → Aug 2015 | systemic mastocytosis | Hospital Virgen de la Salud | Completed | No outcome recorded |
| Phase 4 | NCT02894645 | Oct 2008 → Oct 2018 | childhood acute lymphoblastic leukemia | National University Hospital, Singapore | Unknown | Met primary |
| Phase 4 | NCT01491763 | Jan 2008 → Dec 2022 | precursor lymphoblastic lymphoma/leukemia | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT00372476 | Jun 2006 → Jul 2012 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00171899 | Apr 2005 → Jun 2007 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00171977 | Jul 2004 → Apr 2009 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00845221 | Jul 2004 → Nov 2011 | chronic myeloid leukemia | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00081926 | Oct 2003 → Mar 2007 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00390897 | Jul 2003 → Oct 2006 | chronic myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT05722795 | Jun 2023 → Jun 2029 expected | triple-negative breast carcinoma | Vastra Gotaland Region | Recruiting | No outcome recorded |
| — | NCT03862768 | Jul 2019 → Jun 2021 | gastrointestinal stromal tumor | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT01343173 | Apr 2011 → May 2017 | chronic myeloid leukemia | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01316250 | Aug 2010 → Jul 2025 | chronic myeloid leukemia | American University of Beirut Medical Center | Completed | No outcome recorded |
| — | NCT01114087 | Oct 2008 → May 2009 | chronic myeloid leukemia, gastrointestinal stromal tumor | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00538109 | Oct 2007 → Oct 2013 | chronic myeloid leukemia | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00386373 | Aug 2003 → Oct 2007 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00049569 | Jan 2003 → Mar 2006 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00038675 | Jun 2001 → Nov 2013 | acquired polycythemia vera, chronic myeloid leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome +1 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00854841 | — | chronic myeloid leukemia | Pusan National University Hospital | Available | No outcome recorded |
| — | NCT01613053 | — | gastrointestinal stromal tumor | Novartis Pharmaceuticals | No longer available | No outcome recorded |
| Comparator or background therapy96 trials | ||||||
| Phase 0 | NCT03228303 Comparator | Dec 2017 → Jul 2020 | chronic myeloid leukemia | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT06889168 Comparator | Oct 2025 → Dec 2026 expected | lymphangioleiomyomatosis | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT06655246 Background | Mar 2025 → Dec 2027 expected | gastrointestinal stromal tumor | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05623774 Comparator | Dec 2022 → Jun 2024 | chronic myeloid leukemia | Inhibikase Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03328117 Comparator | Nov 2017 → Mar 2018 | acute lung injury | Exvastat Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02129166 Comparator | Sep → Oct 2014 | — | University of Florida | Withdrawn | No outcome recorded |
| Phase 1 | NCT02081378 Background | Apr 2014 → Jun 2021 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01751425 Background | Jul 2013 → Sep 2019 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00686218 Background | May 2008 → Mar 2013 | leukemia | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00483366 Background | Aug 2006 → Jan 2009 | cancer of unknown primary site | University of Nebraska | Completed | No outcome recorded |
| Phase 1 | NCT00324077 Background | Aug 2006 → Feb 2007 | chronic myeloid leukemia | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00301093 Background | Sep 2005 → May 2007 | leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00066326 Background | Jun 2003 → Oct 2004 | leukemia | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT04006847 Background | Sep 2020 → May 2021 | chronic myeloid leukemia | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02257541 Background | Oct 2014 → Mar 2019 | gastrointestinal stromal tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01188889 Background | Sep 2013 → Dec 2016 | chronic myeloid leukemia | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00784446 Comparator | Apr 2008 → Aug 2010 | colorectal cancer | University of Cologne | Completed | No outcome recorded |
| Phase 1/2 | NCT00219765 Background | May 2001 → Jan 2006 | chronic myeloid leukemia | Poitiers University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT07493408 Background | Mar 2026 → Dec 2035 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), blast phase chronic myelogenous leukemia, BCR-ABL1 positive, disease related to hematopoietic stem cell transplant | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05152472 Background | Jan 2022 → Oct 2027 expected | gastrointestinal stromal tumor | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2 | NCT04838041 Background | Nov 2021 → Jun 2028 expected | chronic myeloid leukemia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT06219733 Comparator | Jun 2021 → May 2022 | dermoid cyst | MedPacto, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04794088 Comparator | Mar 2021 → Mar 2022 | COVID-19, acute respiratory distress syndrome, pulmonary edema | Dr. Jurjan Aman | Terminated | No outcome recorded |
| Phase 2 | NCT04688983 Comparator | Jan 2021 → Jan 2024 | adult acute lymphoblastic leukemia | Cardiff University | Unknown | No outcome recorded |
| Phase 2 | NCT04626024 Background | Dec 2020 → Nov 2028 expected | chronic myeloid leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04126681 Comparator | Oct 2019 → Aug 2024 | chronic myeloid leukemia | Ascentage Pharma Group Inc. | Completed | Met primary |
| Phase 2 | NCT03906292 Background | Aug 2019 → Dec 2027 expected | chronic myeloid leukemia | University of Jena | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03516279 Background | Jun 2019 → Aug 2028 expected | chronic myeloid leukemia | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03389256 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03654768 Background | Oct 2018 → Jul 2024 overdue | chronic myeloid leukemia | SWOG Cancer Research Network | Active not recruiting | Missed primary |
| Phase 2 | NCT04883125 Comparator | Jan 2018 → Apr 2021 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT02687425 Background | Feb → Nov 2016 | chronic myeloid leukemia | Meng Li | Unknown | No outcome recorded |
| Phase 2 | NCT02001818 Background | Apr 2014 → Jan 2022 | chronic myeloid leukemia | Australasian Leukaemia and Lymphoma Group | Completed | No outcome recorded |
| Phase 2 | NCT01593254 Comparator | Sep 2012 → Nov 2017 | chronic myeloid leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01429610 Background | Nov 2011 → Jan 2018 | precursor lymphoblastic lymphoma/leukemia | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01503502 Comparator | Aug 2011 → Jun 2012 | chronic myeloid leukemia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01312818 Background | Jun 2011 → Jan 2013 | acute lymphoblastic leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01097694 Comparator | Nov 2010 → Aug 2015 | asthma | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01227135 Background | Mar 2010 → Mar 2012 | leukemia | Lynn McMahon | Unknown | No outcome recorded |
| Phase 2 | NCT01011998 Background | Sep 2009 → Jun 2010 | chronic myeloid leukemia | New Mexico Cancer Research Alliance | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01005914 Background | Jun 2009 → Mar 2013 | leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00882206 Background | Apr 2009 → Jan 2013 | leukemia, lymphoma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00852566 Comparator | Mar 2009 → Feb 2011 | chronic myeloid leukemia | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT01089595 Comparator | Feb 2009 → Nov 2011 | gastrointestinal stromal tumor, metastatic neoplasm | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00427999 Background | Feb 2007 → Jun 2015 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00415909 Background | Dec 2006 → May 2013 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00415857 Background | Dec 2006 → Sep 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00455559 Background | Aug 2006 → Nov 2010 | gastrointestinal stromal tumor | AEterna Zentaris | Completed | No outcome recorded |
| Phase 2 | NCT00320190 Comparator | Aug 2006 → Jan 2010 | chronic myeloid leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00267085 Background | Dec 2005 → Jul 2008 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00110058 Background | Feb 2005 → Jul 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00209079 Comparator | Sep 2004 → Apr 2007 | gastric adenocarcinoma | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01227356 Background | Sep 2004 → Mar 2009 | — | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT00154336 Comparator | Jul 2004 → Aug 2005 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00058747 Background | Mar 2003 → Apr 2006 | chronic myeloid leukemia | Agenus Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00036738 Background | Jul 2001 → Jul 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT06821542 Background | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06682169 Comparator | Nov 2024 → Oct 2029 expected | chronic graft versus host disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04971226 Comparator | Oct 2021 → Nov 2023 overdue | chronic myeloid leukemia | Novartis Pharmaceuticals | Active not recruiting | Met primary |
| Phase 3 | NCT04722848 Comparator | Sep 2021 → Sep 2027 expected | adult acute lymphoblastic leukemia | GIMEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03722420 Comparator | Dec 2018 → Mar 2023 overdue | chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03589326 Comparator | Oct 2018 → Aug 2022 overdue | acute lymphoblastic leukemia | Takeda | Active not recruiting | Met primary |
| Phase 3 | NCT03639922 Comparator | Oct 2018 → Dec 2022 | ischemic stroke | Niaz Ahmed | Unknown | No outcome recorded |
| Phase 3 | NCT03515018 Comparator | May 2018 → May 2020 | chronic myeloid leukemia | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03112603 Comparator | Jun 2017 → May 2020 | chronic graft versus host disease | Incyte Corporation | Completed | Met primary |
| Phase 3 | NCT02576080 Comparator | Oct 2015 → Oct 2019 | gastrointestinal stromal tumor | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT02272777 Comparator | Jul 2014 → Jan 2017 | leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02130557 Comparator | Jul 2014 → Aug 2016 | chronic myeloid leukemia | Pfizer | Completed | Met primary |
| Phase 3 | NCT02204644 Comparator | Jun 2014 → Jun 2017 | chronic myeloid leukemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01755325 Background | Nov 2012 → Dec 2018 | chronic myeloid leukemia | Junmin Li | Suspended | No outcome recorded |
| Phase 3 | NCT01650805 Comparator | Jun 2012 → Oct 2013 | chronic myeloid leukemia | Ariad Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT01511289 Comparator | Aug 2011 → Feb 2015 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01275196 Comparator | Apr 2011 → Oct 2014 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01031628 Comparator | Jan 2010 → Jun 2011 | gastrointestinal stromal tumor | Sarcoma Alliance for Research through Collaboration | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00760877 Comparator | Jun 2009 → Jul 2015 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00751036 Comparator | Jun 2009 → Aug 2012 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00956072 Comparator | May 2009 → Mar 2011 | gastrointestinal stromal tumor | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00802841 Comparator | May 2009 → Jul 2014 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00785785 Comparator | Mar 2009 → Oct 2014 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT01400074 Comparator | Jan 2009 → Jun 2014 | chronic myeloid leukemia | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00812240 Comparator | Jan 2009 → Jul 2018 | gastrointestinal stromal tumor | AB Science | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01460693 Comparator | Aug 2008 → Mar 2018 | chronic myeloid leukemia | Newcastle University | Completed | No outcome recorded |
| Phase 3 | NCT00574873 Comparator | Feb 2008 → Aug 2010 | chronic myeloid leukemia | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00519090 Comparator | Oct 2007 → Oct 2008 | myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00481247 Comparator | Sep 2007 → Dec 2009 | chronic myeloid leukemia | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT00372567 Comparator | Jun 2007 → Nov 2009 | gastrointestinal stromal tumor | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00362466 Comparator | Apr 2007 → Jun 2008 | leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00471328 Background | Mar 2007 → Aug 2008 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00116935 Comparator | Feb 2004 → Dec 2010 | sarcoma | Scandinavian Sarcoma Group | Completed | No outcome recorded |
| Phase 3 | NCT00050531 Background | Apr 2003 → Apr 2007 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 4 | NCT05367765 Comparator | Apr 2022 → Apr 2027 expected | chronic myeloid leukemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05071482 Comparator | Sep 2021 → Jan 2023 | acute leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| Phase 4 | NCT01578213 Background | Nov 2011 → Nov 2018 | chronic myeloid leukemia | University of Milano Bicocca | Completed | No outcome recorded |
| Phase 4 | NCT00510354 Background | Oct 2006 → Nov 2012 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| — | NCT05751733 Comparator | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| — | NCT01085617 Background | Dec 2010 → Feb 2025 | leukemia, mouth disorder, mucositis | University College, London | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Novartis Pharmaceuticals | Results Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML novartis.com ↗
The longer-term data showed a progressively larger difference in MMR rates favorable to Scemblix vs. SoC TKIs, vs. imatinib and vs. 2G TKIs 1 . |
| 2024-05-31 | Novartis Pharmaceuticals | Results Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML novartis.com ↗ |
| 2024-05-15 | Novartis Pharmaceuticals | Results Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA novartis.com ↗
The primary results from ASC4FIRST, a pivotal Phase III study of Scemblix ® (asciminib) versus standard of care tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, and bosutinib) in newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) will be shared at the ASCO official Press Program and at the EHA Plenary Session. |
| 2024-01-08 | Novartis Pharmaceuticals | Results Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia novartis.com ↗ |
| 2022-11-17 | Takeda | Results Phase 3 Trial of ICLUSIG ® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US takeda.com ↗
Primary Endpoint Result Shows Superiority Compared to Imatinib as Assessed by MRD-Negative Complete Remission |
| 2022-05-23 | Tenax Therapeutics, Inc. | Results Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension tenaxthera.com ↗
The pharmacokinetic data from this trial showed that TNX-201 significantly exceeded Tenax’ relative bioavailability threshold (area under the curve (AUC)) when compared to reference Gleevec® tablets. |
| 2020-04-09 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Imatinib Mesylate Tablets zyduslife.com ↗
Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. |
| 2019-06-14 | Novartis Pharmaceuticals | Results Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) novartis.com ↗
Separate data demonstrate promising results for asciminib (ABL001), an investigational allosteric BCR-ABL inhibitor, in combination with three different tyrosine kinase inhibitors (TKIs) in heavily pre-treated Ph+ CML-CP patients. |
| 2019-03-06 | NATCO Pharma Ltd. | Regulatory NATCO and its alliance partner Lupin receive FDA approval for lmatinib Mesylate Tablets natcopharma.co.in ↗
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for lmatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). |
| 2019-03-05 | Lupin Limited | Regulatory Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets lupin.com ↗
announced the final ANDA approval for Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) from the United States Food and Drug Administration (FDA) |
| 2019-01-21 | Wockhardt | Regulatory WOCKHARDT RECEIVES US FDA APPROVAL FOR LEUKEMIA DRUG wockhardt.com ↗
Wockhardt has received approval from th e United States Food & Drug Administration (US FDA) for an ANDA for 100mg and 400mg tablets o f Imatinib Mesylate |
| 2016-12-05 | Pfizer | Results Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia pfizer.com ↗
Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE ( B osutinib trial in F irst line chr O nic myelogenous leukemia t RE atment) trial demonstrating superiority of BOSULIF® (bosutinib) over imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). |
| 2015-12-04 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces US FDA approval for generic Gleevec® sunpharma.com ↗ |
| 2013-12-09 | Bristol-Myers Squibb | Results Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology bms.com ↗
At four years, 76% of Sprycel patients vs. 63% of imatinib patients achieved a major molecular response (MMR). |
| 2010-12-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results Follow-Up Results from Study Comparing SPRYCEL (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data®*1 otsuka.co.jp ↗
Results at 18 months were consistent with 12 month data in which SPRYCEL demonstrated higher and faster rates of complete cytogenetic response (CCyR) and major molecular response (MMR) compared to imatinib. |
| 2010-12-06 | Bristol-Myers Squibb | Results Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data bms.com ↗
Results at 18 months were consistent with 12 month data in which SPRYCEL demonstrated higher and faster rates of complete cytogenetic response (CCyR) and major molecular response 1 (MMR) compared to imatinib. |
| 2010-06-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results SPRYCEL (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevecin Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase®®* otsuka.co.jp ↗
Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response(CCyR) compared to Gleevec (imatinib mesylate). |
| 2010-06-05 | Bristol-Myers Squibb | Results SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response(CCyR) † compared to Gleevec ® (imatinib mesylate). |
| 2005-12-12 | Astex Pharmaceuticals, Inc. | Results Dacogen™ (Decitabine) Injection Data Presented at American Society of Hematology (ASH) Annual Meeting astx.com ↗
Data from a phase 2 study of Dacogen injection in combination with imatinib in patients with chronic myelogenous leukemia (CML) were presented in a poster session on Saturday, December 10. |
All press releases naming this drug 41 releases
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 545 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imatinib | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗386“Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial,...” NCT01613053 ↗ “This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib...” NCT04903730 ↗ “Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and PDGFRA which is...” PMID 21140148 ↗ Dec 2010 “* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the...” NCT05273242 ↗ “Participants received either the reference (4 tablets of 100-mg imatinib) or the test (1 tablet of 400-mg imatinib) formulation during the first period and the alternative...” PMID 24060561 ↗ Sep 2013 “Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct” NCT01153750 ↗ “Doses are halved/reduced per protocol: Flumatinib 400/200 mg QD, Imatinib 200 mg QD, Nilotinib 300 mg QD, Dasatinib 50 mg QD, or Olverembatinib 20 mg QD, based on pre-entry therapy.” NCT07839988 ↗ “With the BCR/ABL protein TKI, imatinib, in the combination chemotherapy regimes for newly diagnosed Ph+ ALL, more than 95% of patients can achieve complete remission(CR).” NCT01883219 ↗ “Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia” NCT01316250 ↗ “This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST.” NCT00135005 ↗ |
| Known as | AV-101 | “AV-101 (imatinib) administered via dry powder inhalation” NCT05036135 ↗ |
| Known as | Gleevec | “A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic...” NCT00103844 ↗60“A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous...” NCT00081133 ↗ “The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in...” NCT00044304 ↗ “A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete...” NCT00093639 ↗ “Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing...” PMID 16914578 ↗ Aug 2006 “The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.” NCT00955916 ↗ “The identification of KIT+ tumor has become more important after introduction of target treatment with KIT tyrosine kinase inhibitor Imatinib mesylate (Gleevec).” NCT00290485 ↗ “A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia” NCT00245128 ↗ “A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML” NCT00268229 ↗ “Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia.” NCT00573326 ↗ “Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase” NCT00538109 ↗ |
| Known as | Gleevec (imatinib mesylate) | “Gleevec (imatinib mesylate)” NCT00558961 ↗ |
| Known as | Gleevec(Registered Trademark) | “This study will evaluate the safety and effectiveness of imatinib (Gleevec(Registered Trademark)) in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic...” NCT00079313 ↗ |
| Known as | Gleevec-Imatinib-Imatinib mesylate | “Gleevec-Imatinib-Imatinib mesylate” NCT00613132 ↗ |
| Known as | Glevec | “Imatinib 600mg/day (Glevec is the brand name for imatinib)” NCT01275222 ↗ |
| Known as | Glinib | “A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia...” NCT02204722 ↗ |
| Known as | Glivec | “An Exploratory Single Center Study of High-dose Treatment of Glivec® in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)...” NCT01216085 ↗29“Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e....” NCT00085475 ↗ “Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib...” NCT00103168 ↗ “A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete...” NCT00093639 ↗ “Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or...” NCT00112632 ↗ “Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT” NCT00180921 ↗ “Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months” NCT04070443 ↗ “Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia” NCT01316250 ↗ “The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as:” NCT00276926 ↗ “Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase” NCT00538109 ↗ “Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy.” NCT02896842 ↗ |
| Known as | GLIVECÔ | “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVECÔ, Novartis Pharma)” NCT00510926 ↗ |
| Known as | IMA | “We profiled peripheral blood cell transcriptomes at imatinib (IMA) discontinuation in patients from the multicenter STIM2 trial (n = 96) to develop a transcriptome-based model...” PMID 42454992 ↗ Jun 2026 |
| Known as | Imatinib (STI571): Gleevec | “Imatinib (STI571): Gleevec” NCT01400074 ↗ |
| Known as | Imatinib Mesilate | “Over-encapsulated 100 mg imatinib mesilate tablets” NCT03328117 ↗ |
| Known as | Imatinib Mesylate | “Systemic sclerosis (SSc) is an autoimmune disease in which the tyrosine kinases platelet-derived growth factor receptor (PDGFR) and Abl are hypothesized to contribute to the...” PMID 19180499 ↗ Feb 2009195“A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic...” NCT00103844 ↗ “The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in...” NCT00044304 ↗ “The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the...” NCT00928525 ↗ “Imatinib mesylate (trade names: Glivec® and Gleevec®, imatinib, formerly STI571) is a signal transduction inhibitor targeting several protein-tyrosine kinases that are believed...” NCT01172548 ↗ “AIMS: Imatinib mesylate, as add-on therapy in patients with pulmonary arterial hypertension (PAH) who remain inadequately treated despite receiving at least two PAH-specific...” PMID 24566799 ↗ Feb 2014 “An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients...” NCT02614404 ↗ “Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing...” PMID 16914578 ↗ Aug 2006 “To determine the maximum tolerable dose and assess the safety and tolerability of imatinib mesylate in combination with capecitabine and cisplatin in patients with unresectable...” NCT00601510 ↗ “To identify the maximum tolerated dose of imatinib (imatinib mesylate) in patients with recurrent oligodendroglioma and mixed oligoastrocytoma that are currently on enzyme...” NCT00049127 ↗ “Imatinib mesylate is a potent inhibitor of platelet-derived growth factor and transforming growth factor-β signalling pathways which may play a role in systemic sclerosis...” PMID 23039171 ↗ Oct 2012 |
| Known as | Imatinib Mesylate (Gleevec, STI571), NSC 716051, IND 61,135 | “Imatinib Mesylate (Gleevec, STI571), NSC 716051, IND 61,135” NCT00891527 ↗ |
| Known as | Impentri | “Intravenous Imatinib Mesylate (Impentri®)” NCT04794088 ↗ |
| Known as | Megavec | “Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers” NCT01653314 ↗ |
| Known as | NCS 716051 | “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ |
| Known as | NSC #716051 | “Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas” NCT01140360 ↗1“Imatinib Mesylate (Gleevec®; STI571; NSC #716051)” NCT01991379 ↗ |
| Known as | QTI571 | “A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of...” NCT00902174 ↗3“Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized...” PMID 26210752 ↗ Jun 2015 “An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension:...” NCT01117987 ↗ |
| Known as | STI 571 | “A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous...” NCT00081133 ↗44“This is a single center, four-treatment, four period, crossover study to evaluate the effect of food on the relative bioavailability of a single dose of imatinib (STI571) given...” NCT00422825 ↗ “PRIMARY OBJECTIVES: I. To assess the feasibility of a Southwest Oncology Group Phase II trial or oral STI-571/imatinib (Gleevec) administered to patients with metastatic or...” NCT00068783 ↗ “Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute...” NCT00744081 ↗ “Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer” NCT00038194 ↗ “A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML” NCT00268229 ↗ “Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia.” NCT00573326 ↗ “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ “Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas” NCT01140360 ↗ “Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies” NCT00064285 ↗ “The goal of this clinical research study is to see if imatinib mesylate (Gleevec, STI571) can improve CML in chronic phase.” NCT00048672 ↗ |
| Action | Inhibit | “Imatinib, a selective BCR-ABL1 kinase inhibitor” PMID 28273028 ↗ Mar 2017 |
| Modality | Small molecule | “Imatinib mesylate is a small molecule” PMID 19303137 ↗ Mar 2009 |
| Route | Oral | “Patients with Ph chromosome-positive status receive oral imatinib mesylate once daily for at least 28 days” NCT00002514 ↗ |
| Target | KIT | “Imatinib (STI571) inhibits a similar tyrosine kinase, BCR-ABL, leading to responses in chronic myeloid leukaemia, and has also been shown to inhibit KIT.” PMID 11705489 ↗ Oct 2001 |
| Target | PDGFRA | “Previous studies have shown that activating mutations of c-KIT/PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the pathophysiology of...” PMID 15010069 ↗ Mar 2004 |